In diabetic claims patients, exenatide use was not associated with increased acute renal failure risk versus diabetic controls.
In plain wordsIn patients with diabetes, exenatide use was not linked to higher acute kidney failure risk than control medications.
- Peptide
- Exenatide (exendin-4)
- Outcome
- No significant changeAcute renal failure risk
- Study
n: not reported in source
- Comparator
- Diabetic controls
- Outcome group
- Kidney function · Kidney and urinary
- Studied dose
- Dose not stated
Measurements
- Hazard ratio
- 0.77 ratio
- exenatide versus diabetic controls
Source sentences
Compared with diabetic controls, neither exenatide (HR 0.77, CI 0.42-1.41, p = 0.40) nor sitagliptin (HR 1.17, CI 0.82-1.65, p = 0.39) increased the risk of ARF.
2 context sentences(design, population, supporting numbers)
A retrospective cohort study of a large medical and pharmacy claims database was performed.
Cox proportional hazard models were used to compare the risk of ARF between diabetic and non-diabetic subjects and between diabetic patients treated with exenatide, sitagliptin and control medications.